<p><strong><span class&equals;"legendSpanClass"><span class&equals;"xn-location">CUPERTINO <&sol;span>and <span class&equals;"xn-location">MUMBAI&comma; India <&sol;span><&sol;span><&sol;strong>&&num;8212&semi; <u><a href&equals;"https&colon;&sol;&sol;c212&period;net&sol;c&sol;link&sol;&quest;t&equals;0&amp&semi;l&equals;en&amp&semi;o&equals;4308165-1&amp&semi;h&equals;1175823305&amp&semi;u&equals;https&percnt;3A&percnt;2F&percnt;2Fwww&period;onecelldx&period;com&percnt;2F&amp&semi;a&equals;OneCell&plus;Diagnostics" target&equals;"&lowbar;blank" rel&equals;"nofollow noopener">OneCell Diagnostics<&sol;a><&sol;u>&comma; a genomics-based precision oncology company&comma; has raised &dollar;16 million in an oversubscribed Series A funding round led by Celesta Capital&comma; with participation from Tenacity Ventures&comma; Cedars Sinai&comma; Eragon&comma; and Singularity Ventures&period; The funding will be used to advance its vision of democratizing precision oncology through cancer diagnostic testing that is more accessible&comma; actionable&comma; and affordable&period; Celesta Capital Founding Managing Partner Michael Marks and Nobel Laureate and Celesta Capital Senior Advisor Dr&period; <span class&equals;"xn-person">James Rothman<&sol;span> will join the OneCell board of directors&period;<&sol;p>&NewLine;<p>OneCell has developed cutting-edge technology for precision oncology liquid biopsy diagnostics&period; Their cancer screening tests are based on a proprietary Circulating Tumor Cell &lpar;CTC&rpar; and True-Single-Cell-Multi-omics platform&comma; supporting a range of applications in clinical cancer care and early-stage clinical trials for biotech and pharma companies&period; OneCell&&num;8217&semi;s cell biopsy technology integrates CTC-DNA with CTC-RNA and cell surface protein testing&comma; all from a single blood draw&comma; a significant advancement over current &&num;8220&semi;liquid biopsy&&num;8221&semi; testing&period;<&sol;p>&NewLine;<p>&&num;8220&semi;We see a future where everyone has access to high-quality&comma; life-saving cancer testing and this funding is a powerful validation of our vision&comma;&&num;8221&semi; said <span class&equals;"xn-person">Mohan Uttarwar<&sol;span>&comma; CEO and Co-founder at OneCell Diagnostics&period; &&num;8220&semi;By integrating our single-cell multi-omics analytics with next-generation liquid biopsy approaches&comma; we have the opportunity to break new ground in delivering accurate&comma; personalized cancer care worldwide&period;&&num;8221&semi;<&sol;p>&NewLine;<p>With this Series A funding&comma; OneCell will expand to the U&period;S&period; market with its next-generation liquid biopsy test&comma; OncoIndx Ikon&period; The test detects and analyzes CTCs&comma; which offer rich biomarkers that advance precision diagnosis and treatment of cancer for use cases including treatment response monitoring&comma; disease progression&comma; recurrence&comma; and more&period; Through its global operations in Silicon Valley and in <span class&equals;"xn-location">India<&sol;span>&comma; the company has already introduced a range of products in <span class&equals;"xn-location">India<&sol;span>&comma; where it has tested nearly ten thousand patients to date and demonstrated that its cell biopsy technology can be implemented easily&comma; safely&comma; and cost-effectively at any lab worldwide&period; The company&&num;8217&semi;s growing list of strategic academic and industry partners include <span class&equals;"xn-org">Harvard Medical School<&sol;span>&comma; <span class&equals;"xn-org">Stanford University<&sol;span>&comma; and other leading medical institutions&period;<&sol;p>&NewLine;<p>&&num;8220&semi;Celesta is excited about differentiated companies sitting at the intersection of high tech and biomedical science&comma; and OneCell fits this mold perfectly&comma;&&num;8221&semi; said <span class&equals;"xn-person">Michael Marks<&sol;span>&comma; Founding Managing Partner at Celesta Capital&period; &&num;8220&semi;By leveraging the strategic benefits of the U&period;S&period; &&num;8211&semi; <span class&equals;"xn-location">India<&sol;span> corridor&comma; OneCell is well-positioned to continue building competitive advantages&period; We pride ourselves on being active value-add investors and Celesta will tap our ecosystem to support their growth wherever possible&period;&&num;8221&semi;<&sol;p>&NewLine;<p>&&num;8220&semi;I&&num;8217&semi;m looking forward to joining the OneCell Board at such a pivotal time in the arc of innovation for cancer treatment&comma;&&num;8221&semi; said Dr&period; <span class&equals;"xn-person">James Rothman<&sol;span>&comma; Nobel Laureate and Celesta Capital Advisor&period; &&num;8220&semi;Cell biopsy represents a groundbreaking shift in how we approach diagnostics&comma; creating more opportunities for highly individualized care&period; This technology has the potential to reshape the oncology landscape&comma; and we are eager to support OneCell&&num;8217&semi;s bold mission to reach more than 1000 oncologists and 1 million patients in the near future&period;&&num;8221&semi;<&sol;p>&NewLine;